Document is current
Any future updates will be listed below
-
Authors
Lundberg, Oscar H. M. https://orcid.org/0000-0002-9295-6944
Lengquist, Maria
Spångfors, Martin
Annborn, Martin
Bergmann, Deborah
Schulte, Janin
Levin, Helena
Melander, Olle
Frigyesi, Attila
Friberg, Hans
-
Funding
Funding for this research was provided by:
Region Skåne
Biobanking and BioMolecular resources Research Infrastructurey
Trolle-Wachtmeister Foundation for Medical Research
European Union Interreg programme IV A.
Lund University
- License Information
-
More Information
Article History
Received: 2 June 2020
Accepted: 16 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: The study was approved by the Regional Ethical Committee in Lund, Sweden, with reference numbers DNR 2015/267 and DNR 2017/802. An opt-out procedure made a withdrawal of participation possible.
: Not applicable.
: OL, ML, MS, MA, HL, AF and HF declare that they have no competing interests, no financial or any other interests in SphingoTec GmbH and have not been in any way influenced by SphingoTec GmbH in writing this research paper. OM is listed as an inventor on a patent on bio-ADM in dementia prediction. SphingoTec GmbH is the owner of the patent. DB and JS are employed by SphingoTec GmbH and participate in the company’s employee stock option program. Bioactive ADM was analysed free of charge by SphingoTec GmbH, Neuendorfstrae 15A, 16761 Hennigsdorf, Germany.
